MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Aandelen Lijst・Cassava Sciences Inc

Cassava Sciences Inc

Gesloten

SectorGezondheidszorg

2.03 -4.69

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.02

Max

2.04

Belangrijke statistieken
By Trading Economics
Inkomsten	33M -11M
Verkoop	840K 840K
Winstmarge	-1,286.548
Werknemers	30
EBITDA	35M -11M

Dividenden
By Dow Jones
Volgende Winsten	2 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-4.3M 142M
Vorige openingsprijs	6.72
Vorige sluitingsprijs	2.03

Nieuwssentiment

By Acuity

50%

138 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

1.56 / 1.7 Steun & Weerstand

Cassava Sciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 dec 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dec 2025, 23:39 UTC

Belangrijke Marktbewegers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

Peer Vergelijking

Prijswijziging

Cassava Sciences Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Cassava Sciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.56 / 1.7Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

138 / 361 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.